amlodipine has been researched along with Disease Models, Animal in 109 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pentylenetetrazole was used to induce acute seizures which mimic status epilepticus." | 7.85 | Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice. ( Khan, RA; Qureshi, IH; Riaz, A; Siddiqui, AA, 2017) |
| "The present study aims to study the role of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin (RANKL/RANK/OPG) system in cardiac hypertrophy in a spontaneous hypertension rat (SHR) model and the effects of amlodipine and atorvastatin intervention." | 7.83 | Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. ( Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X, 2016) |
| " In both experimental models and clinical cases of vasodilatory shock, methylene blue improves hemodynamic measures." | 7.81 | Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock. ( Bania, TC; Chu, J; Donovan, S; Hoffman, RS; Jang, DH; Nelson, LS, 2015) |
| " We have previously shown that in salt-sensitive hypertension either a statin or the calcium channel blocker amlodipine (Aml) have vasoprotective effects." | 7.80 | Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. ( Jaimes, EA; Raij, L; Tian, R; Zhou, MS, 2014) |
| "Urinary calculi are a common and severe problem, which are formed by urolithiasis or by the formation of calcium oxalate (CaOx) crystals in the kidneys." | 7.79 | The biochemical and histopathological investigation of amlodipine in ethylene glycol-induced urolithiasis rat model. ( Albayrak, A; Bayir, Y; Colak, S; Dorman, E; Gulcan, E; Halici, Z; Karakus, E; Keles, MS; Oral, A; Uludag, K; Yayla, N; Zipak, T, 2013) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "Clinical studies have indicated the beneficial effect of an L/N-type calcium channel blocker (CCB), cilnidipine, on the progression of proteinuria in hypertensive patients compared with an L-type CCB, amlodipine." | 7.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| "3 to 3 mg/kg per day) and calcium channel blocker amlodipine (1 mg/kg per day), and the effects on stroke (n=61) and brain superoxide were compared between them." | 7.73 | Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005) |
| " Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine." | 7.73 | The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. ( Enomoto, A; Konda, T; Matsushita, J; Moriyama, T; Takahara, A, 2005) |
| "The synergistic effect of nicorandil (K(ATP) channel opener) and amlodipine (calcium channel blocker) on lysosomal hydrolases in serum and heart was examined by determining the activity of beta-glucuronidase, beta-N-acetyl glucosaminidase, beta-galactosidase, cathepsin-D and acid phosphatase on isoproterenol-induced myocardial infarction in rats." | 7.72 | Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Amlodipine (a new class of calcium channel antagonist) has been shown to limit the progression of arteriosclerosis and decrease the incidence of cardiovascular events." | 7.72 | Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. ( Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kataoka, C; Kitamoto, S; Ni, W; Takeshita, A; Usui, M, 2004) |
| "We sought to determine whether reperfusion and the calcium channel blocker amlodipine or the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ)." | 7.71 | Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. ( Idikio, H; Jugdutt, BI; Kumar, D; Menon, V, 2002) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 7.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "Past studies have suggested that amlodipine, a dihydropyridine L-type Ca(2+) channel antagonist, may exert useful effects in congestive heart failure (CHF)." | 7.71 | Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility. ( Clair, MJ; Gay, DM; Goldberg, A; Hendrick, JW; Jolly, JR; King, MK; McElmurray, JH; Mukherjee, R; Patterson, TM; Spinale, FG, 2001) |
| "This study examined the acute effects of amlodipine treatment on left ventricular pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF), both at rest and with treadmill exercise." | 7.70 | Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. ( Clair, MJ; Dodd, MG; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG, 1999) |
| "Amlodipine improves exercise capacity in patients with chronic congestive heart failure (HF), but the mechanisms of this effect are unknown." | 7.70 | Vascular and cardiac effects of amlodipine in acute heart failure in dogs. ( Belenkie, I; Isaac, DL; Manyari, DE; Tyberg, JV, 1998) |
| "The dihydropyridine calcium channel blocking agent amlodipine is an effective anti-hypertensive agent and its use (in doses of 5 or 10 mg/day/kg body weight) was investigated in male Wistar rats with hypertension induced by aortic constriction." | 7.69 | Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. ( Patel, VB; Preedy, VR; Richardson, PJ; Sherwood, R; Siddiq, T, 1997) |
| "Amlodipine appears to have a protective effect against myocardial injury in this animal model of congestive heart failure." | 7.69 | Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. ( Matsui, S; Matsumori, A; Okada, I; Sasayama, S; Sato, Y; Shioi, T; Shiota, K; Suzuki, H; Wang, WZ; Yamada, T, 1997) |
| "Ischemic stroke is a major neurologic disorder and a leading cause of disability and death in the world." | 5.37 | Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. ( Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T, 2011) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | 5.35 | Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| "Body weight was measured weekly in all the groups, and arterial blood pressure was also measured in all the 10-, 15-, 20-, and 25-week-old SHR by the tail cuff method." | 5.32 | Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. ( Aleixandre, A; Civantos, B, 2003) |
| "Amlodipine was the preferred calcium antagonist for this study because it is only moderately negatively inotropic." | 5.29 | Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. ( Aupetit, JF; Bui-Xuan, B; Faucon, G; Timour, Q, 1996) |
| "Amlodipine overdoses have significant cardiac toxicity and are difficult to treat." | 4.02 | Efficacy of methylene blue in a murine model of amlodipine overdose. ( Baccanale, CL; de Castro Brás, LE; Eccleston, L; Meggs, WJ; O'Rourke, D; Pittman, P; Sloan, T; St Antoine, JC; Verzwyvelt, SM, 2021) |
| " Pentylenetetrazole was used to induce acute seizures which mimic status epilepticus." | 3.85 | Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice. ( Khan, RA; Qureshi, IH; Riaz, A; Siddiqui, AA, 2017) |
| "The present study aims to study the role of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin (RANKL/RANK/OPG) system in cardiac hypertrophy in a spontaneous hypertension rat (SHR) model and the effects of amlodipine and atorvastatin intervention." | 3.83 | Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. ( Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X, 2016) |
| " In both experimental models and clinical cases of vasodilatory shock, methylene blue improves hemodynamic measures." | 3.81 | Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock. ( Bania, TC; Chu, J; Donovan, S; Hoffman, RS; Jang, DH; Nelson, LS, 2015) |
| "Spontaneously hypertensive rats (SHR) was used to study left ventricular hypertrophy (LVH) and its dynamic change after the interventions with Telmisartan and Amlodipine." | 3.81 | TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats. ( Chen, L; Hong, H; Lin, X; Shi, X; Wu, Y; Zou, G, 2015) |
| " We have previously shown that in salt-sensitive hypertension either a statin or the calcium channel blocker amlodipine (Aml) have vasoprotective effects." | 3.80 | Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. ( Jaimes, EA; Raij, L; Tian, R; Zhou, MS, 2014) |
| " To address this issue, we examined the difference between the effects of amlodipine (an L-type Ca(2+) channel blocker) and cilnidipine (a dual L/N-type Ca(2+) channel blocker) on fibrotic changes using a rat unilateral ureteral obstruction (UUO) model." | 3.79 | Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats. ( Hiromura, K; Ikeuchi, H; Maeshima, A; Mishima, K; Miya, M; Nojima, Y; Sakurai, N, 2013) |
| "Urinary calculi are a common and severe problem, which are formed by urolithiasis or by the formation of calcium oxalate (CaOx) crystals in the kidneys." | 3.79 | The biochemical and histopathological investigation of amlodipine in ethylene glycol-induced urolithiasis rat model. ( Albayrak, A; Bayir, Y; Colak, S; Dorman, E; Gulcan, E; Halici, Z; Karakus, E; Keles, MS; Oral, A; Uludag, K; Yayla, N; Zipak, T, 2013) |
| "Amlodipine is capable of mitigating the negative effects of orchidectomy and could be a good prevention of osteoporosis." | 3.78 | Protective effect of amlodipine on rat bone tissue after orchidectomy. ( Gradosova, I; Hubena, S; Palicka, V; Svejkovska, K; Zivna, H; Zivny, P, 2012) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| " Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
| "Clinical studies have indicated the beneficial effect of an L/N-type calcium channel blocker (CCB), cilnidipine, on the progression of proteinuria in hypertensive patients compared with an L-type CCB, amlodipine." | 3.76 | Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. ( Asanuma, K; Fan, YY; Fujita, T; Hitomi, H; Kobori, H; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohashi, N; Ohsaki, H; Suwarni, D; Tomino, Y, 2010) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "For the acute study, in the maximal electroshock seizure model, the administration of 1 mg/kg of amlodipine resulted in the complete abolition of seizures in 33 percent of the mice, and this was increased to 67 percent with the administration of 4 mg/kg." | 3.76 | An experimental study of the anticonvulsant effect of amlodipine in mice. ( Sathyanarayana Rao, KN; Subbalakshmi, NK, 2010) |
| "Calcium ion (Ca(2+)) influx into the optic nerve (ON) through VDCCs was investigated in a rat model of optic neuritis using manganese-enhanced magnetic resonance imaging and in vivo calcium imaging." | 3.75 | Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. ( Bähr, M; Boretius, S; Diem, R; Fairless, R; Frahm, J; Gadjanski, I; Hochmeister, S; Knöferle, J; Lingor, P; Michaelis, T; Sättler, MB; Storch, MK; Sühs, KW; Williams, SK, 2009) |
| "The present study examined the levels of Angiotensin II type 1 receptor (AT(1)) and type 2 receptor (AT(2)) in the brain stem and cerebral cortex of the stroke-prone spontaneously hypertensive rat (SHR-sp) after long-term treatment with three types of antihypertensive drugs: valsartan, enalapril, and amlodipine." | 3.74 | Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat. ( Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y, 2008) |
| " In the present study, we evaluated the effect of an ARB, olmesartan medoxomil (CS866), on the progression of peritoneal fibrosis in peritoneal dialysis by examining its effect in a model of peritoneal fibrosis in hypertensive rats." | 3.74 | Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. ( Fukushima, R; Imai, H; Ishida, Y; Nakamoto, H; Suzuki, H; Yamanouchi, Y, 2008) |
| "Although amlodipine, a long-acting L-type calcium channel blocker, reportedly prevents left ventricular remodeling and dysfunction after myocardial infarction, the mechanism responsible is not yet well understood." | 3.74 | Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. ( Aoyama, T; Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kawasaki, M; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007) |
| "3 to 3 mg/kg per day) and calcium channel blocker amlodipine (1 mg/kg per day), and the effects on stroke (n=61) and brain superoxide were compared between them." | 3.73 | Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005) |
| " Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine." | 3.73 | The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. ( Enomoto, A; Konda, T; Matsushita, J; Moriyama, T; Takahara, A, 2005) |
| "We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/CRP) transgenic mice." | 3.73 | Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. ( de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A, 2006) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "The synergistic effect of nicorandil (K(ATP) channel opener) and amlodipine (calcium channel blocker) on lysosomal hydrolases in serum and heart was examined by determining the activity of beta-glucuronidase, beta-N-acetyl glucosaminidase, beta-galactosidase, cathepsin-D and acid phosphatase on isoproterenol-induced myocardial infarction in rats." | 3.72 | Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "Amlodipine (a new class of calcium channel antagonist) has been shown to limit the progression of arteriosclerosis and decrease the incidence of cardiovascular events." | 3.72 | Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. ( Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kataoka, C; Kitamoto, S; Ni, W; Takeshita, A; Usui, M, 2004) |
| "Our objective was to examine the effect of chronic treatment with amlodipine on blood pressure, left ventricular hypertrophy, and fibrosis in spontaneously hypertensive rats and the persistence of such an effect after drug withdrawal." | 3.72 | Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. ( Ardanaz, N; Arévalo, MA; Carrón, R; Guerrero, EI; Montero, MJ; San Román, L; Sevilla, MA; Voces, F, 2004) |
| "We sought to determine whether reperfusion and the calcium channel blocker amlodipine or the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ)." | 3.71 | Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. ( Idikio, H; Jugdutt, BI; Kumar, D; Menon, V, 2002) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 3.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "We measured detailed left ventricular remodeling parameters in vivo (echocardiograms) repeatedly over 6 weeks and ex vivo (planimetry) at 6 weeks after myocardial infarction in 36 dogs randomized (factorial design) after reperfused or nonreperfused myocardial infarction to 6 weeks of twice daily oral therapy with the calcium channel blocker amlodipine (5 mg), the angiotensin-converting enzyme inhibitor enalapril (5 mg) or placebo, and 18 matching sham or control animals." | 3.71 | Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters. ( Jugdutt, BI; Menon, V, 2002) |
| "Past studies have suggested that amlodipine, a dihydropyridine L-type Ca(2+) channel antagonist, may exert useful effects in congestive heart failure (CHF)." | 3.71 | Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility. ( Clair, MJ; Gay, DM; Goldberg, A; Hendrick, JW; Jolly, JR; King, MK; McElmurray, JH; Mukherjee, R; Patterson, TM; Spinale, FG, 2001) |
| "To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.71 | Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002) |
| "Amlodipine improves exercise capacity in patients with chronic congestive heart failure (HF), but the mechanisms of this effect are unknown." | 3.70 | Vascular and cardiac effects of amlodipine in acute heart failure in dogs. ( Belenkie, I; Isaac, DL; Manyari, DE; Tyberg, JV, 1998) |
| "Abdominal aortic aneurysms are characterised by changes in the extracellular matrix of the arterial media, in particular a reduction in elastin concentration." | 3.70 | Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease. ( Bell, PR; Boyle, JR; Crowther, M; Goodall, S; Loftus, IM; Thompson, MM, 1998) |
| "This study examined the acute effects of amlodipine treatment on left ventricular pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF), both at rest and with treadmill exercise." | 3.70 | Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. ( Clair, MJ; Dodd, MG; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG, 1999) |
| "To compare the effects of the calcium channel blocker amlodipine with those of the angiotensin-converting enzyme (ACE) inhibitor enalapril on left ventricular (LV) remodelling and dysfunction during healing after reperfused anterior myocardial infarction (MI)." | 3.69 | Effects of amlodipine versus enalapril on left ventricular remodelling after reperfused anterior myocardial canine infarction. ( Jugdutt, BI, 1997) |
| "Amlodipine appears to have a protective effect against myocardial injury in this animal model of congestive heart failure." | 3.69 | Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. ( Matsui, S; Matsumori, A; Okada, I; Sasayama, S; Sato, Y; Shioi, T; Shiota, K; Suzuki, H; Wang, WZ; Yamada, T, 1997) |
| "The dihydropyridine calcium channel blocking agent amlodipine is an effective anti-hypertensive agent and its use (in doses of 5 or 10 mg/day/kg body weight) was investigated in male Wistar rats with hypertension induced by aortic constriction." | 3.69 | Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. ( Patel, VB; Preedy, VR; Richardson, PJ; Sherwood, R; Siddiq, T, 1997) |
| "Hypertension is the major risk factor for SVDs, but how hypertension damages the brain microcirculation is unclear." | 1.62 | Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease. ( Dabertrand, F; Ferris, HR; Greenstein, AS; Harraz, OF; Hill-Eubanks, DC; Koide, M; Longden, TA; Nelson, MT; Wellman, GC, 2021) |
| "Once weekly oral dosing of nano-FDC of amlodipine, CNDT and hydrochlorothiazide provided adequate antihypertensive effect and was not statistically different from daily dosing of free drugs in dexamethasone-induced animal model." | 1.56 | Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ( Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020) |
| "Vascular remodeling is an adaptive response to various stimuli, including mechanical forces, inflammatory cytokines and hormones." | 1.56 | Involvement of Angiotensin II Type 1 Receptor and Calcium Channel in Vascular Remodeling and Endothelial Dysfunction in Rats with Pressure Overload. ( Chen, DR; Chen, J; Gao, PJ; Han, WQ; Jiang, H; Ruan, CC, 2020) |
| " We administered this solution to three animals in order to determine a toxic dose, capable of facilitating a two-arm study of amlodipine toxicity." | 1.56 | Development and Feasibility of a Porcine Model of Amlodipine Toxicity. ( Boley, SP; Engebretsen, KM; LeRoy, JM; Mackenzie, RB; Stellpflug, SJ, 2020) |
| "Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta." | 1.46 | Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. ( Berg, G; Bertera, FM; Carranza, A; Chiappetta, DA; Del Mauro, JS; Donato, M; Fernandez Machulsky, N; Gelpi, RJ; González, GE; Gorzalczany, SB; Höcht, C; Morales, C; Morettón, MA; Prince, PD; Taira, CA, 2017) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | 1.42 | Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats. ( Ahmed, MA; El Morsy, EM; Kamel, R, 2015) |
| "Atorvastatin treatment of fructose-fed rats increased vascular BH4 content, which was associated with an increase in endothelial NO synthase activity as well as a reduction in endothelial O2(-) production." | 1.40 | Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. ( Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y, 2014) |
| "Amlodipine increased NO bioavailability and decreased nitroxidative stress in SHRs with EC dysfunction disproportionately to BP changes." | 1.40 | Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. ( Corbalan, JJ; Jacob, RF; Kaliszan, R; Malinski, T; Mason, RP, 2014) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| "Amiloride treatment also reduced high blood pressure caused by the high-salt diet in these mice." | 1.38 | Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. ( Chen, S; Cui, Y; Jiang, J; Peng, J; Shen, J; Wang, W; Wu, Q, 2012) |
| "Ischemic stroke is a major neurologic disorder and a leading cause of disability and death in the world." | 1.37 | Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. ( Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T, 2011) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | 1.35 | Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| "Amlodipine treatment at doses of 1 and 3 mg/kg significantly increased the calcium (P<0." | 1.35 | Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. ( Borekci, B; Cadirci, E; Halici, Z; Ozdemir, Y; Suleyman, H, 2008) |
| "Rosiglitazone-treated rats had restored systolic blood pressure (BP) and normalized plasma insulin level during oral glucose tolerance tests, whereas amlodipine-treated rats restored only systolic BP." | 1.35 | Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats. ( Chen, HS; Juan, CC; Lin, HD; Wu, TE, 2009) |
| "Body weight was measured weekly in all the groups, and arterial blood pressure was also measured in all the 10-, 15-, 20-, and 25-week-old SHR by the tail cuff method." | 1.32 | Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. ( Aleixandre, A; Civantos, B, 2003) |
| "When nicorandil (1 mM) was applied, the following relaxation was 18." | 1.31 | The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil. ( Hirai, M; Iino, S; Kondo, T; Takeshita, K; Tanaka, T, 2002) |
| "The HOCM, diatrizoate, was more toxic to rat kidneys than the LOCM iohexol; PLA2, LPO and calcium load played a role in producing renal function impairment induced by diatrizoate meglumine; amlodipine protected the renal tissue from nephrotoxicity induced by diatrizoate." | 1.31 | Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. ( Duan, SB; Liu, FY; Liu, RH; Luo, JA; Peng, YM; Wu, HW; Yang, XL, 2000) |
| "Intensity of catalepsy was predicted by dopamine D1, D2, and mACh receptor occupancies with the dynamic model which had already been constructed and was compared with the observed values." | 1.30 | Catalepsy induced by calcium channel blockers in mice. ( Haraguchi, K; Iga, T; Ito, K; Kotaki, H; Sawada, Y, 1998) |
| "Hypertension is a complex disease, the treatment of which should not only lower systolic and diastolic blood pressure but also attenuate the secondary consequences of the disease." | 1.29 | End-organ involvement and calcium antagonist therapy: animal studies. ( Nayler, WG, 1994) |
| "Amlodipine was the preferred calcium antagonist for this study because it is only moderately negatively inotropic." | 1.29 | Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. ( Aupetit, JF; Bui-Xuan, B; Faucon, G; Timour, Q, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (15.60) | 18.2507 |
| 2000's | 43 (39.45) | 29.6817 |
| 2010's | 39 (35.78) | 24.3611 |
| 2020's | 10 (9.17) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Yao, KX | 1 |
| Lyu, H | 1 |
| Liao, MH | 1 |
| Yang, L | 1 |
| Gao, YP | 1 |
| Liu, QB | 1 |
| Wang, CK | 1 |
| Lu, YM | 1 |
| Jiang, GJ | 1 |
| Han, F | 1 |
| Wang, P | 1 |
| Naseratun, N | 1 |
| Kobara, M | 2 |
| Watanabe, Y | 1 |
| Toba, H | 2 |
| Nakata, T | 2 |
| Chen, DR | 1 |
| Jiang, H | 1 |
| Chen, J | 2 |
| Ruan, CC | 1 |
| Han, WQ | 1 |
| Gao, PJ | 1 |
| Pandey, AK | 1 |
| Shafiq, N | 1 |
| Bhandari, RK | 1 |
| Rather, IIG | 1 |
| Kaur, N | 1 |
| Bhatia, A | 1 |
| Sharma, S | 1 |
| Malhotra, S | 1 |
| LeRoy, JM | 2 |
| Boley, SP | 2 |
| Corcoran, JN | 1 |
| Engebretsen, KM | 2 |
| Stellpflug, SJ | 2 |
| de Castro Brás, LE | 1 |
| Baccanale, CL | 1 |
| Eccleston, L | 1 |
| Sloan, T | 1 |
| St Antoine, JC | 1 |
| Verzwyvelt, SM | 1 |
| Pittman, P | 1 |
| O'Rourke, D | 1 |
| Meggs, WJ | 1 |
| Uchendu, IK | 1 |
| Agu, CE | 1 |
| Nnedu, EB | 1 |
| Chukwu, IJ | 1 |
| Menger, MM | 1 |
| Merscher, B | 1 |
| Scheuer, C | 1 |
| Braun, BJ | 1 |
| Herath, SC | 1 |
| Rollmann, MF | 1 |
| Stenger, D | 1 |
| Später, T | 1 |
| Pohlemann, T | 1 |
| Menger, MD | 1 |
| Histing, T | 1 |
| Koide, M | 1 |
| Harraz, OF | 1 |
| Dabertrand, F | 1 |
| Longden, TA | 1 |
| Ferris, HR | 1 |
| Wellman, GC | 1 |
| Hill-Eubanks, DC | 1 |
| Greenstein, AS | 1 |
| Nelson, MT | 1 |
| Del Mauro, JS | 1 |
| Prince, PD | 1 |
| Donato, M | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| González, GE | 1 |
| Bertera, FM | 1 |
| Carranza, A | 1 |
| Gorzalczany, SB | 1 |
| Chiappetta, DA | 1 |
| Berg, G | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Taira, CA | 1 |
| Höcht, C | 1 |
| Nelson, JW | 1 |
| Ferdaus, MZ | 1 |
| McCormick, JA | 1 |
| Minnier, J | 1 |
| Kaul, S | 1 |
| Ellison, DH | 1 |
| Barnes, AP | 1 |
| Kaya, H | 1 |
| Polat, B | 1 |
| Albayrak, A | 2 |
| Mercantepe, T | 1 |
| Buyuk, B | 1 |
| Mackenzie, RB | 1 |
| Takahashi, K | 1 |
| Matsumoto, Y | 1 |
| Do e, Z | 1 |
| Kanazawa, M | 1 |
| Satoh, K | 1 |
| Shimizu, T | 2 |
| Sato, A | 1 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Mason, RP | 1 |
| Jacob, RF | 1 |
| Corbalan, JJ | 1 |
| Kaliszan, R | 1 |
| Malinski, T | 1 |
| Okamura, T | 1 |
| Tawa, M | 1 |
| Geddawy, A | 1 |
| Shimosato, T | 1 |
| Iwasaki, H | 1 |
| Shintaku, H | 2 |
| Yoshida, Y | 1 |
| Masada, M | 1 |
| Shinozaki, K | 1 |
| Imamura, T | 1 |
| Zhou, MS | 1 |
| Tian, R | 1 |
| Jaimes, EA | 1 |
| Raij, L | 1 |
| Griffin, KA | 2 |
| Polichnowski, A | 1 |
| Litbarg, N | 1 |
| Picken, M | 1 |
| Venkatachalam, MA | 1 |
| Bidani, AK | 2 |
| Lankhorst, S | 1 |
| Kappers, MH | 1 |
| van Esch, JH | 1 |
| Smedts, FM | 1 |
| Sleijfer, S | 1 |
| Mathijssen, RH | 1 |
| Baelde, HJ | 1 |
| Danser, AH | 1 |
| van den Meiracker, AH | 1 |
| Zou, G | 1 |
| Hong, H | 1 |
| Lin, X | 1 |
| Shi, X | 1 |
| Wu, Y | 1 |
| Chen, L | 1 |
| Jang, DH | 1 |
| Donovan, S | 1 |
| Nelson, LS | 1 |
| Bania, TC | 1 |
| Hoffman, RS | 1 |
| Chu, J | 1 |
| Hasegawa, Y | 1 |
| Nakagawa, T | 1 |
| Uekawa, K | 1 |
| Ma, M | 1 |
| Lin, B | 1 |
| Kusaka, H | 1 |
| Katayama, T | 1 |
| Sueta, D | 2 |
| Toyama, K | 2 |
| Koibuchi, N | 2 |
| Kim-Mitsuyama, S | 5 |
| El Morsy, EM | 1 |
| Kamel, R | 1 |
| Ahmed, MA | 1 |
| Lu, J | 1 |
| Liu, F | 1 |
| Liu, D | 1 |
| Du, H | 1 |
| Hao, J | 1 |
| Yang, X | 1 |
| Cui, W | 1 |
| Gao, XM | 1 |
| Tsai, A | 1 |
| Al-Sharea, A | 1 |
| Su, Y | 1 |
| Moore, S | 1 |
| Han, LP | 1 |
| Kiriazis, H | 1 |
| Dart, AM | 1 |
| Murphy, AJ | 1 |
| Du, XJ | 1 |
| Qureshi, IH | 1 |
| Riaz, A | 1 |
| Khan, RA | 1 |
| Siddiqui, AA | 1 |
| Nakamoto, H | 1 |
| Imai, H | 1 |
| Fukushima, R | 1 |
| Ishida, Y | 1 |
| Yamanouchi, Y | 1 |
| Suzuki, H | 2 |
| Chen, HS | 1 |
| Wu, TE | 1 |
| Juan, CC | 1 |
| Lin, HD | 1 |
| Kamalov, G | 1 |
| Deshmukh, PA | 1 |
| Baburyan, NY | 1 |
| Gandhi, MS | 1 |
| Johnson, PL | 1 |
| Ahokas, RA | 1 |
| Bhattacharya, SK | 1 |
| Sun, Y | 1 |
| Gerling, IC | 1 |
| Weber, KT | 1 |
| Choi, SM | 1 |
| Seo, MJ | 1 |
| Kang, KK | 1 |
| Kim, JH | 1 |
| Ahn, BO | 1 |
| Yoo, M | 1 |
| Gadjanski, I | 1 |
| Boretius, S | 1 |
| Williams, SK | 1 |
| Lingor, P | 1 |
| Knöferle, J | 1 |
| Sättler, MB | 1 |
| Fairless, R | 1 |
| Hochmeister, S | 1 |
| Sühs, KW | 1 |
| Michaelis, T | 1 |
| Frahm, J | 1 |
| Storch, MK | 1 |
| Bähr, M | 1 |
| Diem, R | 1 |
| Khan, AH | 1 |
| Sattar, MA | 2 |
| Abdullah, NA | 2 |
| Johns, EJ | 3 |
| Kang, BY | 1 |
| Wang, W | 3 |
| Palade, P | 1 |
| Sharma, SG | 1 |
| Mehta, JL | 1 |
| Khan, MA | 1 |
| Abdulla, MH | 1 |
| Salman, IM | 1 |
| Kazi, RN | 1 |
| Swarup, KR | 1 |
| Rathore, HA | 1 |
| Basri, F | 1 |
| Hussain, NM | 1 |
| Dewa, A | 1 |
| Chan, SH | 1 |
| Wu, KL | 1 |
| Kung, PS | 1 |
| Chan, JY | 1 |
| Fan, YY | 1 |
| Kohno, M | 1 |
| Nakano, D | 1 |
| Ohsaki, H | 1 |
| Kobori, H | 1 |
| Suwarni, D | 1 |
| Ohashi, N | 1 |
| Hitomi, H | 1 |
| Asanuma, K | 1 |
| Noma, T | 1 |
| Tomino, Y | 1 |
| Fujita, T | 1 |
| Nishiyama, A | 1 |
| Luo, Q | 1 |
| Xuan, WL | 1 |
| Xi, F | 1 |
| Liao, YL | 1 |
| Kitakaze, M | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 1 |
| Tsutsumi, A | 1 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Mazumdar, K | 1 |
| Asok Kumar, K | 1 |
| Dutta, NK | 1 |
| Sathyanarayana Rao, KN | 1 |
| Subbalakshmi, NK | 1 |
| Aritomi, S | 1 |
| Koganei, H | 1 |
| Wagatsuma, H | 1 |
| Mitsui, A | 1 |
| Ogawa, T | 1 |
| Nitta, K | 1 |
| Konda, T | 2 |
| Liu, W | 1 |
| Song, SW | 1 |
| Gu, XF | 1 |
| Ma, XJ | 1 |
| Su, FY | 1 |
| Zhang, H | 1 |
| Liu, AJ | 1 |
| Su, DF | 1 |
| Yoshida, M | 2 |
| Tojo, C | 1 |
| Nakano, A | 1 |
| Oshima, Y | 1 |
| Kojima, Y | 1 |
| Noda, K | 1 |
| Wang, J | 1 |
| Hagita, S | 1 |
| Osaka, M | 1 |
| Shimokado, K | 1 |
| Hirata, Y | 2 |
| Sata, M | 1 |
| Kawai, H | 1 |
| Deguchi, S | 1 |
| Deguchi, K | 1 |
| Yamashita, T | 2 |
| Ohta, Y | 1 |
| Omote, Y | 1 |
| Kurata, T | 1 |
| Ikeda, Y | 1 |
| Matsuura, T | 1 |
| Abe, K | 2 |
| Singh, BK | 1 |
| Pillai, KK | 1 |
| Kohli, K | 1 |
| Haque, SE | 1 |
| Nagasu, H | 1 |
| Satoh, M | 1 |
| Fujimoto, S | 1 |
| Tomita, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Gradosova, I | 1 |
| Zivna, H | 1 |
| Palicka, V | 1 |
| Hubena, S | 1 |
| Svejkovska, K | 1 |
| Zivny, P | 1 |
| Shen, J | 1 |
| Cui, Y | 1 |
| Jiang, J | 1 |
| Chen, S | 1 |
| Peng, J | 1 |
| Wu, Q | 1 |
| Nakamura, T | 1 |
| Dong, YF | 2 |
| Kataoka, K | 2 |
| Yamamoto, E | 3 |
| Yasuda, O | 1 |
| Ogawa, H | 2 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Takayama, K | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Leiria, LO | 1 |
| Sollon, C | 1 |
| Calixto, MC | 1 |
| Lintomen, L | 1 |
| Mónica, FZ | 1 |
| Anhê, GF | 1 |
| De Nucci, G | 1 |
| Zanesco, A | 1 |
| Grant, AD | 1 |
| Antunes, E | 1 |
| Bayir, Y | 2 |
| Halici, Z | 3 |
| Karakus, E | 1 |
| Oral, A | 1 |
| Keles, MS | 1 |
| Colak, S | 1 |
| Zipak, T | 1 |
| Dorman, E | 1 |
| Uludag, K | 1 |
| Yayla, N | 1 |
| Gulcan, E | 1 |
| Fujisawa, M | 1 |
| Yorikane, R | 1 |
| Matsuoka, Y | 1 |
| Koike, H | 1 |
| Ueno, K | 1 |
| Mishima, K | 1 |
| Maeshima, A | 1 |
| Miya, M | 1 |
| Sakurai, N | 1 |
| Ikeuchi, H | 1 |
| Hiromura, K | 1 |
| Nojima, Y | 1 |
| van de Poll, SW | 1 |
| Delsing, DJ | 1 |
| Jukema, JW | 1 |
| Princen, HM | 1 |
| Havekes, LM | 1 |
| Puppels, GJ | 1 |
| van der Laarse, A | 2 |
| Tanaka, T | 2 |
| Iino, S | 1 |
| Takeshita, K | 1 |
| Kondo, T | 1 |
| Hirai, M | 1 |
| Davis, BJ | 1 |
| Cao, Z | 1 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Sathish, V | 1 |
| Ebenezar, KK | 1 |
| Devaki, T | 1 |
| Kataoka, C | 1 |
| Egashira, K | 1 |
| Ishibashi, M | 1 |
| Inoue, S | 1 |
| Ni, W | 1 |
| Hiasa, K | 1 |
| Kitamoto, S | 1 |
| Usui, M | 1 |
| Takeshita, A | 1 |
| Civantos, B | 1 |
| Aleixandre, A | 1 |
| Sevilla, MA | 1 |
| Voces, F | 1 |
| Carrón, R | 1 |
| Guerrero, EI | 1 |
| Ardanaz, N | 1 |
| San Román, L | 1 |
| Arévalo, MA | 1 |
| Montero, MJ | 1 |
| Celik, T | 1 |
| Kayir, H | 1 |
| Ceyhan, M | 1 |
| Demirtaş, S | 1 |
| Coşar, A | 1 |
| Uzbay, IT | 1 |
| Bernobich, E | 1 |
| Cosenzi, A | 1 |
| Campa, C | 1 |
| Zennaro, C | 1 |
| Sasso, F | 1 |
| Paoletti, S | 1 |
| Bellini, G | 1 |
| Zhan, Y | 1 |
| Izumi, Y | 1 |
| Izumiya, Y | 1 |
| Ioroi, T | 1 |
| Wanibuchi, H | 1 |
| Iwao, H | 1 |
| Enomoto, A | 1 |
| Matsushita, J | 1 |
| Takahara, A | 1 |
| Moriyama, T | 1 |
| Di Filippo, C | 1 |
| Lampa, E | 1 |
| Forgione, A | 1 |
| Capuano, A | 1 |
| Rossi, F | 1 |
| D'Amico, M | 1 |
| Lucchesi, BR | 1 |
| Hoff, PT | 1 |
| Tamura, Y | 1 |
| Trion, A | 1 |
| de Maat, M | 1 |
| Jukema, W | 1 |
| Maas, A | 1 |
| Offerman, E | 1 |
| Havekes, L | 1 |
| Szalai, A | 1 |
| Princen, H | 1 |
| Emeis, J | 1 |
| Ikeda, J | 1 |
| Matsubara, M | 1 |
| Yao, K | 1 |
| Toblli, JE | 2 |
| Cao, G | 2 |
| Casas, G | 1 |
| Mazza, ON | 1 |
| Doran, DE | 1 |
| Weiss, D | 1 |
| Zhang, Y | 1 |
| Griendling, KK | 1 |
| Taylor, WR | 1 |
| Mori, Y | 1 |
| Itoh, Y | 1 |
| Tajima, N | 1 |
| Mawatari, E | 1 |
| Hongo, M | 1 |
| Sakai, A | 1 |
| Terasawa, F | 1 |
| Takahashi, M | 1 |
| Yazaki, Y | 1 |
| Kinoshita, O | 1 |
| Ikeda, U | 1 |
| Ogino, A | 1 |
| Takemura, G | 1 |
| Kanamori, H | 1 |
| Okada, H | 1 |
| Maruyama, R | 1 |
| Miyata, S | 1 |
| Esaki, M | 1 |
| Nakagawa, M | 1 |
| Aoyama, T | 1 |
| Ushikoshi, H | 1 |
| Kawasaki, M | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Eftekhari, A | 1 |
| Rahman, A | 1 |
| Schaebel, LH | 1 |
| Chen, H | 1 |
| Rasmussen, CV | 1 |
| Aalkjaer, C | 1 |
| Buus, CL | 1 |
| Mulvany, MJ | 1 |
| Tokutomi, Y | 1 |
| Matsuba, S | 1 |
| Ichijo, H | 1 |
| Borekci, B | 2 |
| Ozdemir, Y | 1 |
| Cadirci, E | 2 |
| Suleyman, H | 2 |
| Karaca, M | 1 |
| Keles, ON | 1 |
| Odabasoglu, F | 1 |
| Unal, B | 1 |
| Muñoz, MC | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Sugahara-Kobayashi, M | 1 |
| Ishikawa, K | 1 |
| Asai, S | 1 |
| Abdul Sattar, M | 1 |
| Nayler, WG | 1 |
| Timour, Q | 1 |
| Bui-Xuan, B | 1 |
| Faucon, G | 1 |
| Aupetit, JF | 1 |
| Wang, WZ | 1 |
| Matsumori, A | 1 |
| Yamada, T | 1 |
| Shioi, T | 1 |
| Okada, I | 1 |
| Matsui, S | 1 |
| Sato, Y | 1 |
| Shiota, K | 1 |
| Sasayama, S | 1 |
| Patel, VB | 1 |
| Siddiq, T | 1 |
| Sherwood, R | 1 |
| Richardson, PJ | 1 |
| Preedy, VR | 1 |
| Bakris, GL | 1 |
| Picken, MM | 1 |
| Jugdutt, BI | 3 |
| de Vries, RJ | 1 |
| Anthonio, R | 1 |
| van Veldhuisen, DJ | 1 |
| Scholtens, E | 1 |
| Buikema, H | 1 |
| van Gilst, WH | 1 |
| Haraguchi, K | 1 |
| Ito, K | 1 |
| Kotaki, H | 1 |
| Sawada, Y | 1 |
| Iga, T | 1 |
| Watanabe, M | 1 |
| Kawaguchi, H | 1 |
| Onozuka, H | 1 |
| Mikami, T | 1 |
| Urasawa, K | 1 |
| Okamoto, H | 1 |
| Watanabe, S | 1 |
| Kitabatake, A | 1 |
| Isaac, DL | 1 |
| Belenkie, I | 1 |
| Manyari, DE | 1 |
| Tyberg, JV | 1 |
| Boyle, JR | 1 |
| Loftus, IM | 1 |
| Goodall, S | 1 |
| Crowther, M | 1 |
| Bell, PR | 1 |
| Thompson, MM | 1 |
| Krombach, RS | 1 |
| Clair, MJ | 2 |
| Hendrick, JW | 2 |
| Mukherjee, R | 2 |
| Houck, WV | 1 |
| Hebbar, L | 1 |
| Kribbs, SB | 1 |
| Dodd, MG | 1 |
| Spinale, FG | 2 |
| Liu, PP | 1 |
| Mak, S | 1 |
| Stewart, DJ | 1 |
| Duan, SB | 1 |
| Liu, FY | 1 |
| Luo, JA | 1 |
| Wu, HW | 1 |
| Liu, RH | 1 |
| Peng, YM | 1 |
| Yang, XL | 1 |
| Yamada, S | 1 |
| Urayama, A | 1 |
| Kimura, R | 1 |
| Watanabe, H | 1 |
| Ohashi, K | 1 |
| McElmurray, JH | 1 |
| Patterson, TM | 1 |
| Goldberg, A | 1 |
| King, MK | 1 |
| Gay, DM | 1 |
| Jolly, JR | 1 |
| Nishikawa, N | 1 |
| Masuyama, T | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Miwa, T | 1 |
| Sugawara, M | 1 |
| Hori, M | 1 |
| Yu, G | 1 |
| Liang, X | 1 |
| Xie, X | 1 |
| Su, M | 1 |
| Zhao, S | 1 |
| Brosnan, MJ | 1 |
| Hamilton, CA | 1 |
| Graham, D | 1 |
| Lygate, CA | 1 |
| Jardine, E | 1 |
| Dominiczak, AF | 1 |
| Gu, Y | 1 |
| Yang, H | 1 |
| Zhu, W | 1 |
| Lin, F | 1 |
| Zhu, C | 1 |
| Lin, S | 1 |
| Menon, V | 2 |
| Kumar, D | 1 |
| Idikio, H | 1 |
| Kloner, RA | 1 |
| Hale, SL | 1 |
| Alker, KJ | 1 |
| Fleckenstein-Grün, G | 1 |
| Frey, M | 1 |
| Thimm, F | 1 |
| Fleckenstein, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study[NCT03255551] | 50 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for amlodipine and Disease Models, Animal
| Article | Year |
|---|---|
Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future.
Topics: Amlodipine; Animals; Anti-Bacterial Agents; Bacterial Infections; Cardiovascular Agents; Disease Mod | 2010 |
Potential role of the microvasculature in progression of heart failure.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiomyopathy, Dilated; Coronary Vessels; Disease Mo | 1999 |
Protective effects of various calcium antagonists against experimental arteriosclerosis.
Topics: Amlodipine; Animals; Arteries; Arteriosclerosis; Calcium Channel Blockers; Disease Models, Animal; H | 1992 |
106 other studies available for amlodipine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia.
Topics: Amlodipine; Animals; Astrocytes; Blood Vessels; Dementia, Vascular; Disease Models, Animal; Mice; Mi | 2019 |
Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Chan | 2020 |
Involvement of Angiotensin II Type 1 Receptor and Calcium Channel in Vascular Remodeling and Endothelial Dysfunction in Rats with Pressure Overload.
Topics: Amlodipine; Animals; Calcium Channels; Carotid Artery Injuries; Constriction, Pathologic; Disease Mo | 2020 |
Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, An | 2020 |
Effect of Methylene Blue on a Porcine Model of Amlodipine Toxicity.
Topics: Amlodipine; Animals; Antidotes; Cardiotoxicity; Cardiovascular Diseases; Cardiovascular System; Dise | 2020 |
Efficacy of methylene blue in a murine model of amlodipine overdose.
Topics: Amlodipine; Animals; Cardiotoxicity; Disease Models, Animal; Drug Overdose; Methylene Blue; Mice; Mi | 2021 |
Combination of aqueous extracts of Curcuma longa (turmeric) and some calcium channel blockers synergistically improves CCl4-induced nephrotoxicity in albino rats.
Topics: Acute Kidney Injury; Amlodipine; Animals; Antioxidants; Calcium Channel Blockers; Carbon Tetrachlori | 2020 |
Amlodipine accelerates bone healing in a stable closed femoral fracture model in mice.
Topics: Amlodipine; Animals; Bone Morphogenetic Protein 2; Bone Remodeling; Bone Screws; Bony Callus; Calciu | 2021 |
Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cerebral Smal | 2021 |
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Blood Pressure Dete | 2017 |
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea | 2018 |
Protective effect of an L-type calcium channel blocker, amlodipine, on paracetamol-induced hepatotoxicity in rats.
Topics: Acetaminophen; Amlodipine; Animals; Anti-Inflammatory Agents; Antioxidants; Calcium Channel Blockers | 2018 |
Development and Feasibility of a Porcine Model of Amlodipine Toxicity.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiotoxicity; Disease Models, Animal; Feasibility S | 2020 |
Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apoptosis; Atorvastatin; Blood Pres | 2013 |
Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Disease Models, Animal; Endothe | 2014 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascu | 2014 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protei | 2014 |
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, | 2014 |
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Topics: Acute Kidney Injury; Amlodipine; Angiogenesis Inhibitors; Animals; Blood Pressure; Disease Models, A | 2014 |
TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Dis | 2015 |
Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Disease Models, Animal; Free Radical Scavengers; Guan | 2015 |
Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Bl | 2016 |
Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Antioxidants; Colitis, Ulcerative; Colon; Dinoproston | 2015 |
Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Cros | 2016 |
Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2017 |
Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice.
Topics: Amlodipine; Animals; Anticonvulsants; Disease Models, Animal; Drug Synergism; Drug Therapy, Combinat | 2017 |
Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Dialysis Solu | 2008 |
Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Chaperonin 60; Diabetes Mellitus, Experimental; Diseas | 2009 |
Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism.
Topics: Aldehydes; Aldosterone; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Dis | 2009 |
Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; A | 2009 |
Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Amlodipine; Amyloid beta-Protein Precursor; Animals; Aut | 2009 |
Effect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Diabetic Nephropathies; Disease Models, Animal; Drug | 2009 |
Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiomegaly; Cholestero | 2009 |
Functional subtypes of renal alpha1-adrenoceptor in spontaneously hypertensive rats with streptozotocin-induced experimental diabetic nephropathy.
Topics: Adrenergic Antagonists; Amlodipine; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2009 |
Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats.
Topics: Administration, Oral; Amlodipine; Analysis of Variance; Animals; Blood Pressure; Disease Models, Ani | 2010 |
Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Topics: Amlodipine; Animals; Base Sequence; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Bloc | 2010 |
[Antihypertrophic effect of dihydropyridines calcium channel blockers is dependent on their potential of blocking N-type calcium channel].
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, N-Type; Cardiomegaly; Dihydropyridi | 2010 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
An experimental study of the anticonvulsant effect of amlodipine in mice.
Topics: Amlodipine; Animals; Anticonvulsants; Calcium Channel Blockers; Convulsants; Disease Models, Animal; | 2010 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazol | 2011 |
L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; C | 2011 |
Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery.
Topics: Adoptive Transfer; Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Cell Adhesion; Disea | 2011 |
Synergistic protection against vascular inflammation with a calcium channel blocker and a statin.
Topics: Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Disease Models, Animal; Dose-Response R | 2011 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; | 2011 |
Isoproterenol-induced cardiomyopathy in rats: influence of Acorus calamus Linn.: A. calamus attenuates cardiomyopathy.
Topics: Acorus; Amlodipine; Animals; Antioxidants; Calcineurin; Cardiomyopathies; Catalase; Disease Models, | 2011 |
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Topics: Amlodipine; Animals; Arterioles; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; | 2012 |
Protective effect of amlodipine on rat bone tissue after orchidectomy.
Topics: Alkaline Phosphatase; Amlodipine; Animals; Biomarkers; Biomechanical Phenomena; Bone and Bones; Bone | 2012 |
Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice.
Topics: Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2012 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
The biochemical and histopathological investigation of amlodipine in ethylene glycol-induced urolithiasis rat model.
Topics: Amlodipine; Ammonium Chloride; Animals; Calcium Channel Blockers; Calcium Oxalate; Disease Models, A | 2013 |
The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
Topics: Administration, Oral; Amlodipine; Angina Pectoris; Animals; Arginine Vasopressin; Azetidinecarboxyli | 2013 |
Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats.
Topics: Actins; Amlodipine; Animals; Cadherins; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium | 2013 |
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosc | 2002 |
The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angioplasty, Balloon, Coronary; Animals; Aorta, Thoracic; | 2002 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats.
Topics: Administration, Oral; Amlodipine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Com | 2003 |
Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Arteriosclerosis; Base Sequence; Blood Pressure; Dise | 2004 |
Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium, Dietary; Cardio | 2003 |
Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response | 2004 |
CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.
Topics: Acetylcholine; Acoustic Stimulation; Alcohol-Induced Disorders, Nervous System; Amlodipine; Animals; | 2004 |
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type | 2004 |
Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen | 2005 |
The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Ca | 2005 |
[Effects of nifedipine controlled release on blood pressure and heart rate of spontaneously hypertensive rats. Comparison with nifedipine standard and with amlodipine].
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2005 |
Cardioprotective effects of amlodipine in animal models of ischemia and reperfusion.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Cats; Coronary Ci | 1991 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pres | 2006 |
Effects of benidipine in a rat model for experimental angina.
Topics: Amlodipine; Angina Pectoris; Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Di | 2006 |
In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
Topics: Acetylcholine; Actins; Adrenergic beta-Antagonists; Amlodipine; Animals; Antihypertensive Agents; Ar | 2006 |
Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Animals; Aorta; Atherosclerosis; Benzimidazoles; Biphe | 2007 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; | 2007 |
Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Blotting, We | 2007 |
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling.
Topics: Amlodipine; Animals; Apoptosis; bcl-Associated Death Protein; Calcineurin; Calcineurin Inhibitors; C | 2007 |
Chronic cystamine treatment inhibits small artery remodelling in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Collagen; Cystamine; Disease Models, A | 2007 |
Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Topics: Acetophenones; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihyp | 2007 |
Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats.
Topics: Amlodipine; Animals; Bone and Bones; Calcium; Calcium Channel Blockers; Dihydropyridines; Disease Mo | 2008 |
Protective effects of amlodipine on ischemia-reperfusion injury of rat ovary: biochemical and histopathologic evaluation.
Topics: Amlodipine; Animals; Antioxidants; Disease Models, Animal; Female; Nitric Oxide; Nitric Oxide Syntha | 2008 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2008 |
Alpha 1-adrenoceptor subtypes mediating adrenergic vasoconstriction in kidney, one-clip Goldblatt and deoxycorticosterone acetate-salt hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Clonidine; Desoxycorticosterone; Disease Models, | 1994 |
End-organ involvement and calcium antagonist therapy: animal studies.
Topics: Administration, Oral; Amlodipine; Animals; Aorta, Thoracic; Arteriosclerosis; Binding Sites; Blood P | 1994 |
Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia.
Topics: Action Potentials; Amlodipine; Animals; Calcium Channel Blockers; Disease Models, Animal; Heart Cond | 1996 |
Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production.
Topics: Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Cardiovirus Infections; Disease Models, | 1997 |
Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Contractile Proteins; Diseas | 1997 |
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Calcium | 1997 |
Effects of amlodipine versus enalapril on left ventricular remodelling after reperfused anterior myocardial canine infarction.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Disease Mod | 1997 |
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Disease Models, Ani | 1997 |
Catalepsy induced by calcium channel blockers in mice.
Topics: Amlodipine; Animals; Binding, Competitive; Calcium Channel Blockers; Catalepsy; Dihydropyridines; Di | 1998 |
Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Calcium; Calcium Channel | 1998 |
Vascular and cardiac effects of amlodipine in acute heart failure in dogs.
Topics: Acute Disease; Amlodipine; Analysis of Variance; Animals; Calcium Channel Blockers; Cardiovascular S | 1998 |
Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease.
Topics: Amlodipine; Animals; Aorta; Aortic Aneurysm; Calcium Channel Blockers; Collagenases; Disease Models, | 1998 |
Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise.
Topics: Amlodipine; Animals; Confounding Factors, Epidemiologic; Coronary Circulation; Disease Models, Anima | 1999 |
Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model.
Topics: Acute Kidney Injury; Amlodipine; Analysis of Variance; Animals; Blood Urea Nitrogen; Calcium; Calciu | 2000 |
Ameliorating effects of amlodipine on plasma and myocardial catecholamines in BIO 53.58 Syrian hamsters, a model of dilated cardiomyopathy.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiomyopathy, Dilated; Catecholamines; Cricetinae; | 2000 |
Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Disease Models, Animal; Heart Failure; Male; Microsco | 2001 |
Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Antihypertensive Agents; Calcium Channel Blockers; Collag | 2001 |
Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2001 |
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort | 2002 |
[The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bosentan; Cilazapril; Diabetes Complications; Diabetes | 2002 |
Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Calcium Channel Blockers; | 2002 |
Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiac Vol | 2002 |
Absence of hemodynamic deterioration in the presence of amlodipine following experimental myocardial infarction.
Topics: Amlodipine; Animals; Coronary Circulation; Disease Models, Animal; Dogs; Electrocardiography; Female | 1992 |